SLABÝ, Ondřej, Petra POKORNÁ, Hana PÁLOVÁ, Michal KÝR, Peter MÚDRY and Jaroslav ŠTĚRBA. Comprehensive genomic profiling and individual therapeutic planning in high-risk/refractory pediatric solid tumors: A single-center real-world study. In 2023 ASCO Annual Meeting I. 2023. ISSN 0732-183X. Available from: https://dx.doi.org/10.1200/JCO.2023.41.16_suppl.10035.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Comprehensive genomic profiling and individual therapeutic planning in high-risk/refractory pediatric solid tumors: A single-center real-world study.
Authors SLABÝ, Ondřej, Petra POKORNÁ, Hana PÁLOVÁ, Michal KÝR, Peter MÚDRY and Jaroslav ŠTĚRBA.
Edition 2023 ASCO Annual Meeting I, 2023.
Other information
Original language English
Type of outcome Konferenční abstrakta
Country of publisher United States of America
Confidentiality degree is not subject to a state or trade secret
WWW URL
Organization Lékařská fakulta – Repository – Repository
ISSN 0732-183X
Doi http://dx.doi.org/10.1200/JCO.2023.41.16_suppl.10035
UT WoS 001053772002601
Keywords in English high-risk/refractory pediatric solid tumors; genomic profiling; individual therapeutic planning
Links LX22NPO5102, research and development project. NU20-03-00240, research and development project.
Changed by Changed by: RNDr. Daniel Jakubík, učo 139797. Changed: 15/11/2023 03:33.
Abstract
gt; 10 mut/Mb). Lymphomas and CNS tumors showed the highest rate of patients with therapeutically actionable findings (60% and 56%, respectively), followed by neuroblastomas (36%), sarcomas (25%), and other solid tumors (23%). All results and individual treatment plans were discussed and approved at multidisciplinary molecular tumor boards. Conclusions: Precision medicine in pediatric oncology has rapidly developed over the last decade and resulted in new therapeutic options based on molecular biomarkers and increased our understanding of the complexity of pediatric malignancies.
Print
Add to clipboard Displayed: 12/7/2024 00:21